Sabcomeline
Clinical data | |
---|---|
ATC code | None |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 159912-58-0 |
PubChem (CID) | 9577995 |
IUPHAR/BPS | 306 |
ChemSpider | 7852359 |
UNII | P8P92V596C Y |
ChEMBL | CHEMBL134641 |
Chemical and physical data | |
Formula | C10H15N3O |
Molar mass | 193.12 g/mol |
3D model (Jmol) | Interactive image |
|
Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease.[1] It made it to phase III clinical trials before being discontinued due to poor results.
See also
References
- ↑ Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1059–68. PMID 9399977.
AChE inhibitors | |
---|---|
Others |
This article is issued from Wikipedia - version of the 9/2/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.